Strontium-89

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Strontium-89
General
Name, symbol Strontium-89,89Sr
Neutrons 51
Protons 38
Nuclide data
Natural abundance syn
Half-life 50.57 days
Decay products 89Y
Decay mode Decay energy
Beta decay

Strontium-89 (89Sr) is a radioactive isotope of strontium produced by nuclear fission, with a half-life of 50.57 days. It undergoes β decay into yttrium-89. Strontium-89 has an application in medicine.[1]

Physiological effects and medical use[edit]

Metastron, a preparation of strontium-89 chloride made by GE Healthcare and used for purposes such as prostate cancer treatment.[2]

Strontium belongs to the same periodic family as calcium (alkaline earth metals), and is metabolised in a similar fashion. 89Sr, used in the treatment of osseous (bony) metastases preferentially targets metabolically active regions of the bone.[3][4] As such, intravenous or intracavity administration of 89Sr may be helpful in the palliation of painful bony metastases, as it allows for targeted radiation to metastatic lesions, inducing apoptosis of cells, membrane and protein damage. Subsequently, bone pain resulting from cytokine release at the site of lesions, bone-associated nerve compression and stretching of the periosteum may be reduced. Treatment with 89Sr has been particularly effective in patients with hormonally-resistant prostate cancer, often leading to a decreased requirement for opioid analgesics, an increase in time until further radiation, and a decrease in tumour markers.

It is an artificial radioisotope which is used in treatment of bone cancer. In circumstances where cancer patients have widespread and painful bony metastases, the administration of 89Sr results in the delivery of beta particles directly to the area of bony problem, where calcium turnover is greatest.[5]

See also[edit]

References[edit]

  1. ^ G. Audi; A. H. Wapstra; C. Thibault; J. Blachot; O. Bersillon (2003). "The NUBASE evaluation of nuclear and decay properties" (PDF). Nuclear Physics A. 729: 3–128. Bibcode:2003NuPhA.729....3A. doi:10.1016/j.nuclphysa.2003.11.001. 
  2. ^ "Strontium 89 (Metastron™) treatment". QEH Birmingham. NHS. Retrieved 23 November 2015. 
  3. ^ Halperin, Edward C.; Perez, Carlos A.; Brady, Luther W. (2008). Perez and Brady's principles and practice of radiation oncology. Lippincott Williams & Wilkins. pp. 1997–. ISBN 978-0-7817-6369-1. Retrieved 19 July 2011. 
  4. ^ Bauman, Glenn; Charette, Manya; Reid, Robert; Sathya, Jinka (2005). "Radiopharmaceuticals for the palliation of painful bone metastases—a systematic review". Radiotherapy and Oncology. 75 (3): 258.E1–258.E13. doi:10.1016/j.radonc.2005.03.003. ISSN 0167-8140. 
  5. ^ Mertens, W. C.; Filipczak, L. A.; Ben-Josef, E.; Davis, L. P.; Porter, A. T. (1998). "Systemic bone-seeking radionuclides for palliation of painful osseous metastases: current concepts". CA: A Cancer Journal for Clinicians. 48 (6): 361–374. doi:10.3322/canjclin.48.6.361. ISSN 0007-9235.